The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Multiplex Genome Engineering Using CRISPR/Cas Systems
Open accessAbstract
Genome Editing: Clustered regularly interspaced short palindromic repeats (CRISPR) function as part of an adaptive immune system in a range of prokaryotes: Invading phage and plasmid DNA is targeted for cleavage by complementary CRISPR RNAs (crRNAs) bound to a CRISPR-associated endonuclease (see the Perspective by van der Oost ). Cong et al. (p. 819 , published online 3 January) and Mali et al. (p. 823 , published online 3 January) adapted this defense system to function as a genome editing tool in eukaryotic cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CRISPR/Cas9 is a class of ribonucleoprotein complexes formed by a Cas9 protein and a single guide RNA (sgRNA) (Jinek et al., 2012; Cho et al., 2013; Cong et al., 2013; Wang et al., 2016a).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Cong et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cas9 is guided by a 20 nt fraction of the gRNA”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and it maintains cleaving activity even with 3-5 mismatches at the PAM-distal end of the gRNA molecule [59,81,102].”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In January 2013, almost simultaneously, five research articles authored by different research teams appeared, all reporting that they had achieved the goal.”
From CRISPR–Cas9: A History of Its Discovery and Ethical Considerations of Its Use in Genome Editing (2022) · cites this paper as [35]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Repurposing bacterial “CRISPR” systems to facilitate RNA-guided cleavage of complementary DNA has revolutionized the field of gene editing in mammalian cells 1–4.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Target specificity of the CRISPR/Cas system is very high and a single mutation can disrupt targeting 20”
From Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus (2013) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“Cas9 can create DNA cleavage at desired genomic positions that are guided by precise base pairing between sgRNA and DNA, adjacent to a protospacer-adjacent motif (PAM) (Jinek et al., 2012; Cho et al., 2013; Cong et al., 2013; Wang et al., 2016a).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Cong et al., 2013
The cited source says what the claim attributes to it.
In the citing paper
“By introducing an aspartate-to-alanine (D10A) mutation in the RuvC active domain of Cas9, the resulting mutant, Cas9 nickase, (Cas9n) will nick the target DNA, originating single-stranded breaks rather than DSB [54,81].”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Cas9n nicks the target DNA, originating single-stranded breaks rather than DSB [54,81].”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“by introducing a specific mutation in the RuvC domain of Cas9, a Cas9 nickase variant (Cas9n) is created.”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“The markedly high efficiency of CRISPR/Cas systems coupled with the above-mentioned advantages over other methods justify the CRISPR “epidemic” that the scientific community experienced in 2013 [62,81,100,101].”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“The pigs were engineered to carry 69 genomic edits, using the clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9)-mediated nonhomologous end joining and homology-directed repair30,31, and recombinase-mediated cassette exchange32 (Fig. 2a, Extended Data Fig. 1a and Supplementary Table 2).”
From Design and testing of a humanized porcine donor for xenotransplantation (2023) · cites this paper as [30]
In the citing paper
“When a double-stranded break is introduced into genomic DNA, cells can repair the break by using a DNA molecule with high sequence similarity as a template. If an artificial template is provided while the DNA break is introduced, this pathway provides a mean to incorporate desired DNA sequences into the genome34,35”
From CRISPR-based functional genomics for neurological disease (2020) · cites this paper as [34]
In the citing paper
“The discovery, made less than 10 years ago, that a simple two-component system of a Cas protein (Streptococcus pyogenes Cas9) bound to a single guide RNA (sgRNA) can function as a programmable nuclease33 that can be deployed to cleave specific sequences in mammalian genomes34,35 has been transformative for biomedical research and the development of gene therapies.”
From CRISPR-based functional genomics for neurological disease (2020) · cites this paper as [34]
In the citing paper
“The CRISPR/Cas9 system has been used for multiplex genome cleavage.20”
From The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo (2014) · cites this paper as [20]
In the citing paper
“Recently, the CRISPR/Cas system has been successfully applied to human cells19,20,21,22 and several model organisms for genome editing.23,24,25,26”
From The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo (2014) · cites this paper as [20]
In the citing paper
“selection of LTR-A-and -B-directed, 30-bp protospacer and also precrRNA system reflecting the original bacterial immune mechanism to enhance specificity/efficiency vs. 20-bp protospacer-based, chimeric crRNA-tracRNA system”
From RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection (2014) · cites this paper as [16]
In the citing paper
“as mentioned in several recent publications, Cas9 tolerates mismatches between the guide RNA and target DNA in a sequence-dependent manner and potentially tolerates up to five target mismatches in human cells [12], [24], [25], [26], [27], thereby promoting undesired off-target mutations.”
From High-efficiency targeted editing of large viral genomes by RNA-guided nucleases (2014) · cites this paper as [12]
In the citing paper
“Because the sequence specificity of Streptococcus pyogenes Cas9 tolerates 4 mismatches between the gRNA and complementary sequence”
From High-efficiency targeted editing of large viral genomes by RNA-guided nucleases (2014) · cites this paper as [12]
In the citing paper
“Compared with well-known, site-specific genome editing technologies, such as ZFNs and TALENs, the new CRISPR-Cas approach is more convenient and efficient [10], [12].”
From High-efficiency targeted editing of large viral genomes by RNA-guided nucleases (2014) · cites this paper as [12]
In the citing paper
“non-specific cleavage may occur in the cellular genome [12], [24], [25], [26], [27].”
From High-efficiency targeted editing of large viral genomes by RNA-guided nucleases (2014) · cites this paper as [12]
In the citing paper
“Clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 is a naturally occurring bacterial immune system that uses a novel nuclease system to protect bacteria from phage infection (6-9), and it has recently been harnessed for a variety of genome-engineering applications (10)(11)(12)(13)(14)(15)(16)(17).”
From RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection (2014) · cites this paper as [11]
In the citing paper
“In the few available publications using CRISPR/Cas9 system, the gene editing frequency is comparable with ZFN or TALEN [87].”
From Newer Gene Editing Technologies toward HIV Gene Therapy (2013) · cites this paper as [87]
In the citing paper
“Collectively, these studies indicate that although each base within the 20 nt guide sequence contributes to overall specificity”
From Newer Gene Editing Technologies toward HIV Gene Therapy (2013) · cites this paper as [87]
In the citing paper
“As described by Zhang group [87], CRISPR/Cas 9 system can be easily employed to target multiple sites to induce a deletion of a large gene fragment.”
From Newer Gene Editing Technologies toward HIV Gene Therapy (2013) · cites this paper as [87]
In the citing paper
“multiple mismatches between the guide RNA and its complementary target DNA sequence can be tolerated depending on the quantity, position, and base identity of mismatches [87,90,91,93], all of which contribute to potential off-target activity.”
From Newer Gene Editing Technologies toward HIV Gene Therapy (2013) · cites this paper as [87]
In the citing paper
“Moreover, no significant cytotoxicity was observed [87,88].”
From Newer Gene Editing Technologies toward HIV Gene Therapy (2013) · cites this paper as [87]
In the citing paper
“while in December 2012 Zhang and the Broad Institute also submitted a patent application [43] simultaneously with the acceptance of Zhang’s paper on human cells’ editing for publication in Science [35].”
From CRISPR–Cas9: A History of Its Discovery and Ethical Considerations of Its Use in Genome Editing (2022) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Gasiunas, G., Barrangou, R., Horvath, P., & Siksnys, V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208507109 · Cited by 2,769
Mechanisms of gene silencing by double-stranded RNA
Meister, G., & Tuschl, T. (2004) · Nature · doi:10.1038/nature02873 · Cited by 2,598
CRISPR RNA Maturation by Trans-Encoded Small RNA and Host Factor RNase III
Deltcheva, E., Chylinski, K., Sharma, C. M., Gonzales, K., Chao, Y., Pirzada, Z. A., Eckert, M. R., Vogel, J., & Charpentier, E. (2011) · Nature · doi:10.1038/nature09886 · Cited by 2,563
CRISPR/Cas, the Immune System of Bacteria and Archaea
Horvath, P., & Barrangou, R. (2010) · Science · doi:10.1126/science.1179555 · Cited by 2,471
Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors
Boch, J., Scholze, H., Schornack, S., Landgraf, A., Hahn, S., Kay, S., Lahaye, T., Nickstadt, A., & Bonas, U. (2009) · Science · doi:10.1126/science.1178811 · Cited by 2,470
Small CRISPR RNAs Guide Antiviral Defense in Prokaryotes
Brouns, S. J. J., Jore, M. M., Lundgren, M., Westra, E. R., Slijkhuis, R. J. H., Snijders, A. P. L., Dickman, M. J., Makarova, K. S., Koonin, E. V., & van der Oost, J. (2008) · Science · doi:10.1126/science.1159689 · Cited by 2,460
The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA
Garneau, J. E., Dupuis, M.-È., Villion, M., Romero, D. A., Barrangou, R., Boyaval, P., Fremaux, C., Horvath, P., Magadán, A. H., & Moineau, S. (2010) · Nature · doi:10.1038/nature09523 · Cited by 2,336
Evolution and classification of the CRISPR–Cas systems
Makarova, K. S., Haft, D. H., Barrangou, R., Brouns, S. J. J., Charpentier, E., Horvath, P., Moineau, S., Mojica, F. J. M., Wolf, Y. I., Yakunin, A. F., et al. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2577 · Cited by 2,331
Cited by
Sorted by citations
Items 301–400 of 1,215
Gao, Y., & Zhao, Y. (2013) · Journal of Integrative Plant Biology · doi:10.1111/jipb.12152 · Cited by 574
Highly Improved Gene Targeting by Germline-Specific Cas9 Expression in Drosophila
Kondo, S., & Ueda, R. (2013) · Genetics · doi:10.1534/genetics.113.156737 · Cited by 580
Wang, H.-X., Li, M., Lee, C. M., Chakraborty, S., Kim, H.-W., Bao, G., & Leong, K. W. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00799 · Cited by 560
Ishino, Y., Krupovic, M., & Forterre, P. (2018) · Journal of Bacteriology · doi:10.1128/jb.00580-17 · Cited by 558
Generation of gene-modified mice via Cas9/RNA-mediated gene targeting
Shen, B., Zhang, J., Wu, H., Wang, J., Ma, K., Li, Z., Zhang, X., Zhang, P., & Huang, X. (2013) · Cell Research · doi:10.1038/cr.2013.46 · Cited by 511
Heckl, D., Kowalczyk, M. S., Yudovich, D., Belizaire, R., Puram, R. V., McConkey, M. E., Thielke, A., Aster, J. C., Regev, A., & Ebert, B. L. (2014) · Nature Biotechnology · doi:10.1038/nbt.2951 · Cited by 555
Chemical pulldown reveals dynamic pseudouridylation of the mammalian transcriptome
Li, X., Zhu, P., Ma, S., Song, J., Bai, J., Sun, F., & Yi, C. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1836 · Cited by 576
Mancias, J. D., Pontano Vaites, L., Nissim, S., Biancur, D. E., Kim, A. J., Wang, X., Liu, Y., Goessling, W., Kimmelman, A. C., & Harper, J. W. (2015) · eLife · doi:10.7554/elife.10308 · Cited by 552
Allele-selective lowering of mutant HTT protein by HTT–LC3 linker compounds
Li, Z., Wang, C., Wang, Z., Zhu, C., Li, J., Sha, T., Ma, L., Gao, C., Yang, Y., Sun, Y., et al. (2019) · Nature · doi:10.1038/s41586-019-1722-1 · Cited by 551
Lawrenson, T., Shorinola, O., Stacey, N., Li, C., Østergaard, L., Patron, N., Uauy, C., & Harwood, W. (2015) · Genome Biology · doi:10.1186/s13059-015-0826-7 · Cited by 551
A Cas9–guide RNA complex preorganized for target DNA recognition
Jiang, F., Zhou, K., Ma, L., Gressel, S., & Doudna, J. A. (2015) · Science · doi:10.1126/science.aab1452 · Cited by 562
Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9
Gupta, R. M., & Musunuru, K. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72992 · Cited by 577
Stimuli-Responsive Nanomaterials for Biomedical Applications
Blum, A. P., Kammeyer, J. K., Rush, A. M., Callmann, C. E., Hahn, M. E., & Gianneschi, N. C. (2014) · Journal of the American Chemical Society · doi:10.1021/ja510147n · Cited by 548
Lü, Y., Xue, J., Deng, T., Zhou, X., Yu, K., Deng, L., Huang, M., Yi, X., Liang, M., Wang, Y., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0840-5 · Cited by 553
The promise of organ and tissue preservation to transform medicine
Giwa, S. E., Lewis, J. K., Alvarez, L. M., Langer, R., Roth, A. E., Church, G. M., Markmann, J. F., Sachs, D. H., Chandraker, A. K., Wertheim, J. A., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3889 · Cited by 557
Editing plant genomes with CRISPR/Cas9
Belhaj, K., Chaparro‐Garcia, A., Kamoun, S., Patron, N. J., & Nekrasov, V. (2014) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2014.11.007 · Cited by 559
Genome Engineering with Targetable Nucleases
Carroll, D. (2014) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060713-035418 · Cited by 568
Miller, J. B., Zhang, S., Kos, P., Xiong, H., Zhou, K., Perelman, S. S., Zhu, H., & Siegwart, D. J. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201610209 · Cited by 540
Generating genetically modified mice using CRISPR/Cas-mediated genome engineering
Yang, H., Wang, H., & Jaenisch, R. (2014) · Nature Protocols · doi:10.1038/nprot.2014.134 · Cited by 554
Neuroblastoma is composed of two super-enhancer-associated differentiation states
van Groningen, T., Köster, J., Valentijn, L. J., Zwijnenburg, D. A., Akogul, N., Hasselt, N. E., Broekmans, M. E. C., Haneveld, F., Nowakowska, N. E., Bras, J., et al. (2017) · Nature Genetics · doi:10.1038/ng.3899 · Cited by 556
DNA Replicons for Plant Genome Engineering
Baltes, N. J., Gil‐Humanes, J., Čermák, T., Atkins, P., & Voytas, D. F. (2014) · The Plant Cell · doi:10.1105/tpc.113.119792 · Cited by 552
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
Benmebarek, M.-R., Karches, C. H., Cadilha, B. L., Lesch, S., Endres, S., & Kobold, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061283 · Cited by 557
CRISPR/Cas system: recent advances and future prospects for genome editing
Manghwar, H., Lindsey, K., Zhang, X., & Jin, S. (2019) · Trends in Plant Science · doi:10.1016/j.tplants.2019.09.006 · Cited by 529
“introduces in vitro dsDNA breaks at a specific site containing a sequence complementary to crRNA [45]”
BackgroundRNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection
Hu, W., Kaminski, R., Yang, F., Zhang, Y., Cosentino, L., Li, F., Luo, B., Alvarez-Carbonell, D., Garcia-Mesa, Y., Karn, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405186111 · Cited by 527
Natural selection and infectious disease in human populations
Karlsson, E. K., Kwiatkowski, D. P., & Sabeti, P. C. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3734 · Cited by 546
Caspase-mediated cleavage of phospholipid flippase for apoptotic phosphatidylserine exposure
Segawa, K., Kurata, S., Yanagihashi, Y., Brummelkamp, T. R., Matsuda, F., & Nagata, S. (2014) · Science · doi:10.1126/science.1252809 · Cited by 528
CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors
Wang, D., Zhang, F., & Gao, G. (2020) · Cell · doi:10.1016/j.cell.2020.03.023 · Cited by 539
Self-citationScreening out irrelevant cell-based models of disease
Horvath, P., Aulner, N., Bickle, M., Davies, A. M., Nery, E. D., Ebner, D., Montoya, M. C., Östling, P., Pietiäinen, V., Price, L. S., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.175 · Cited by 525
CRISPR Interference Efficiently Induces Specific and Reversible Gene Silencing in Human iPSCs
Mandegar, M. A., Huebsch, N., Frolov, E. B., Shin, E., Truong, A., Olvera, M. P., Chan, A. H., Miyaoka, Y., Holmes, K., Spencer, C. I., et al. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.01.022 · Cited by 525
Li, H. L., Fujimoto, N., Sasakawa, N., Shirai, S., Ohkame, T., Sakuma, T., Tanaka, M., Amano, N., Watanabe, A., Sakurai, H., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.10.013 · Cited by 471
Programmable RNA Tracking in Live Cells with CRISPR/Cas9
Nelles, D. A., Fang, M. Y., O’Connell, M. R., Xu, J. L., Markmiller, S., Doudna, J. A., & Yeo, G. W.-M. (2016) · Cell · doi:10.1016/j.cell.2016.02.054 · Cited by 544
MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway
Meng, Z., Moroishi, T., Mottier, V., Plouffe, S. W., Hansen, C. G., Hong, A. W., Park, H. W., Mo, J., Lü, W., Lu, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms9357 · Cited by 537
Interpreting the genomic landscape of speciation: a road map for finding barriers to gene flow
Ravinet, M., Faria, R., Butlin, R. K., Galindo, J., Bierne, N., Rafajlović, M., Noor, M. A. F., Mehlig, B., & Westram, A. M. (2017) · Journal of Evolutionary Biology · doi:10.1111/jeb.13047 · Cited by 546
Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing
Ding, Q., Strong, A., Patel, K. M., Ng, S.-L., Gosis, B. S., Regan, S. N., Cowan, C. A., Rader, D. J., & Musunuru, K. (2014) · Circulation Research · doi:10.1161/circresaha.115.304351 · Cited by 522
Cas9-Guide RNA Directed Genome Editing in Soybean
Li, Z., Liu, Z.-B., Xing, A., Moon, B. P., Koellhoffer, J. P., Huang, L., Ward, R. T., Clifton, E., Falco, S. C., & Cigan, A. M. (2015) · PLANT PHYSIOLOGY · doi:10.1104/pp.15.00783 · Cited by 528
Sun, Y., Zhang, X., Wu, C., He, Y., Ma, Y., Hou, H., Guo, X., Du, W., Zhao, Y., & Xia, L. (2016) · Molecular Plant · doi:10.1016/j.molp.2016.01.001 · Cited by 535
Mimitou, E. P., Cheng, A., Montalbano, A., Hao, S., Stoeckius, M., Legut, M., Roush, T., Herrera, A., Papalexi, E., Ouyang, Z., et al. (2019) · Nature Methods · doi:10.1038/s41592-019-0392-0 · Cited by 520
Genome Engineering Using CRISPR-Cas9 System
Cong, L., & Zhang, F. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1862-1_10 · Cited by 536
Self-citationAlsaiari, S. K., Patil, S., Alyami, M., Alamoudi, K. O., Aleisa, F. A., Merzaban, J. S., Li, M., & Khashab, N. M. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b11754 · Cited by 517
Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR
Boettcher, M., & McManus, M. T. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.04.028 · Cited by 539
High-throughput gene targeting and phenotyping in zebrafish using CRISPR/Cas9Preprint
Varshney, G. K., Pei, W., LaFave, M. C., Idol, J., Xu, L., Gallardo, V. E., Carrington, B., Bishop, K. S., Jones, M. S., Li, M., et al. (2015) · Genome Research · doi:10.1101/gr.186379.114 · Cited by 526
Extracellular matrix-based biomaterial scaffolds and the host response
Aamodt, J. M., & Grainger, D. W. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.02.003 · Cited by 509
Advances in fluorescence labeling strategies for dynamic cellular imaging
Dean, K. M., & Palmer, A. E. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1556 · Cited by 525
Defining and improving the genome-wide specificities of CRISPR–Cas9 nucleases
Tsai, S. Q., & Joung, J. K. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.28 · Cited by 523
Comparison of Cas9 activators in multiple species
Chavez, A., Tuttle, M. L., Pruitt, B. W., Ewen‐Campen, B., Chari, R., Ter‐Ovanesyan, D., Haque, S. J., Cecchi, R. J., Kowal, E. J. K., Buchthal, J., et al. (2016) · Nature Methods · doi:10.1038/nmeth.3871 · Cited by 521
CRISPR/Cas9-mediated viral interference in plants
Ali, Z., Abulfaraj, A. A., Idris, A. M., Ali, S., Tashkandi, M., & Mahfouz, M. M. (2015) · Genome biology · doi:10.1186/s13059-015-0799-6 · Cited by 519
Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the FMR1 Gene
Liu, X. S., Wu, H., Krzisch, M., Wu, X., Graef, J. D., Muffat, J., Hnisz, D., Li, C. H., Yuan, B., Xu, C., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.012 · Cited by 520
Self-citationGasset-Rosa, F., Lu, S., Yu, H., Chen, C., Melamed, Z., Guo, L. E., Shorter, J., Cruz, S. D., & Cleveland, D. W. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.038 · Cited by 526
Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
Hu, B., Ren, J., Luo, Y., Keith, B., Young, R. M., Scholler, J., Zhao, Y., & June, C. H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.002 · Cited by 516
CRISPR-Cas: biology, mechanisms and relevance
Hille, F., & Charpentier, E. (2016) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2015.0496 · Cited by 442
Genetically engineered mouse models in oncology research and cancer medicine
Kersten, K., de Visser, K. E., van Miltenburg, M. H., & Jonkers, J. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606857 · Cited by 502
Ding, Q., Regan, S. N., Xia, Y., Oostrom, L. A., Cowan, C. A., & Musunuru, K. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.03.006 · Cited by 459
Quadros, R. M., Miura, H., Harms, D. W., Akatsuka, H., Sato, T., Aida, T., Redder, R. J., Richardson, G. P., Inagaki, Y., Sakai, D., et al. (2017) · Genome biology · doi:10.1186/s13059-017-1220-4 · Cited by 512
Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria
Yosef, I., Manor, M., Kiro, R., & Qimron, U. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500107112 · Cited by 483
BREX is a novel phage resistance system widespread in microbial genomes
Goldfarb, T., Sberro, H., Weinstock, E., Cohen, O., Doron, S., Charpak‐Amikam, Y., Afik, S., Ofir, G., & Sorek, R. (2014) · The EMBO Journal · doi:10.15252/embj.201489455 · Cited by 501
Nanoparticle-Mediated Delivery towards Advancing Plant Genetic Engineering
Cunningham, F. J., Goh, N. S., Demirer, G. S., Matos, J. L., & Landry, M. P. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.03.009 · Cited by 505
Open Targets: a platform for therapeutic target identification and validation
Koscielny, G., An, P., Carvalho‐Silva, D., Cham, J. A., Fumis, L., Gasparyan, R., Hasan, S., Karamanis, N., Maguire, M., Papa, E., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1055 · Cited by 509
Interspecies Chimerism with Mammalian Pluripotent Stem Cells
Wu, J., Platero-Luengo, A., Sakurai, M., Sugawara, A., Gil, M. A., Yamauchi, T., Suzuki, K., Bogliotti, Y. S., Cuello, C., Valencia, M. M., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.036 · Cited by 513
Induced Pluripotent Stem Cells Meet Genome Editing
Hockemeyer, D., & Jaenisch, R. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.04.013 · Cited by 499
“…and Cas9-mediated genome engineering was developed into the platform of choice to generate SSNs and to genetically modify hPSCs (Chen et al., 2015; Cong et al., 2013; Fu et al., 2014; Gonzalez et al., 2014; Gu et al., 2015; Hou et al., 2013; Hsu et al., 2014; Kleinstiver et al., 2016; Liao and…”
BackgroundStructure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing
Yin, H., Song, C.-Q., Suresh, S., Wu, Q., Walsh, S., Rhym, L. H., Mintzer, E., Bolukbasi, M. F., Zhu, L. J., Kauffman, K., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.4005 · Cited by 499
Classification and evolution of type II CRISPR-Cas systems
Chylinski, K., Makarova, K. S., Charpentier, E., & Koonin, E. V. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku241 · Cited by 498
Li, M., Li, X., Zhou, Z., Wu, P., Fang, M., Pan, X., Lin, Q., Luo, W., Wu, G., & Li, H. (2016) · Frontiers in Plant Science · doi:10.3389/fpls.2016.00377 · Cited by 513
Parkinson-associated risk variant in distal enhancer of α-synuclein modulates target gene expression
Soldner, F., Stelzer, Y., Shivalila, C., Abraham, B. J., Latourelle, J. C., Barrasa, M. I., Goldmann, J. E., Myers, R. H., Young, R. A., & Jaenisch, R. (2016) · Nature · doi:10.1038/nature17939 · Cited by 508
Targeted DNA demethylation in vivo using dCas9–peptide repeat and scFv–TET1 catalytic domain fusions
Morita, S., Noguchi, H., Horii, T., Nakabayashi, K., Kimura, M., Okamura, K., Sakai, A., Nakashima, H., Hata, K., Nakashima, K., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3658 · Cited by 508
Predicting the mutations generated by repair of Cas9-induced double-strand breaks
Allen, F., Crepaldi, L., Alsinet, C., Strong, A., Kleshchevnikov, V., Angeli, P. D., Páleníková, P., Khodak, A., Kiselev, V. Y., Kosicki, M., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4317 · Cited by 524
Lander, E. S. (2016) · Cell · doi:10.1016/j.cell.2015.12.041 · Cited by 539
Gonzãlez, F., Zhu, Z., Shi, Z., Lelli, K. M., Verma, N., Li, Q. V., & Huangfu, D. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.05.018 · Cited by 504
A highly specific SpCas9 variant is identified by in vivo screening in yeast
Casini, A., Olivieri, M., Petris, G., Montagna, C., Reginato, G., Maule, G., Lorenzin, F., Prandi, D., Romanel, A., Demichelis, F., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4066 · Cited by 493
Han, K., Jeng, E. E., Hess, G. T., Morgens, D. W., Li, A., & Bassik, M. C. (2017) · Nature Biotechnology · doi:10.1038/nbt.3834 · Cited by 498
Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer
Liu, X., Bao, X., Hu, M., Chang, H., Jiao, M., Cheng, J., Xie, L., Huang, Q., Li, F., & Li, C.-Y. (2020) · Nature · doi:10.1038/s41586-020-2911-7 · Cited by 490
Yarnall, M. T. N., Ioannidi, E. I., Schmitt-Ulms, C., Krajeski, R. N., Lim, J., Villiger, L., Zhou, W., Jiang, K., Garushyants, S. K., Roberts, N., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01527-4 · Cited by 520
Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16
Zhang, X., Crowley, V. M., Wucherpfennig, T. G., Dix, M. M., & Cravatt, B. F. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0279-5 · Cited by 487
Targeted Genome Editing of Sweet Orange Using Cas9/sgRNA
Jia, H., & Wang, N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093806 · Cited by 495
Lin, S., Liu, Q., Lelyveld, V. S., Choe, J., Szostak, J. W., & Gregory, R. I. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.06.001 · Cited by 494
Self-citationCheating evolution: engineering gene drives to manipulate the fate of wild populations
Champer, J., Buchman, A. B., & Akbari, O. S. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2015.34 · Cited by 492
Cas-Designer: a web-based tool for choice of CRISPR-Cas9 target sites
Park, J., Bae, S., & Kim, J. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv537 · Cited by 483
Inducible in vivo genome editing with CRISPR-Cas9
Dow, L. E., Fisher, J., O’Rourke, K. P., Muley, A., Kastenhuber, E. R., Livshits, G., Tschaharganeh, D. F., Socci, N. D., & Lowe, S. W. (2015) · Nature Biotechnology · doi:10.1038/nbt.3155 · Cited by 496
Synthetic biology to access and expand nature's chemical diversity
Smanski, M. J., Zhou, H. L., Claesen, J., Shen, B., Fischbach, M. A., & Voigt, C. A. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2015.24 · Cited by 490
CRISPR/Cas9 Platforms for Genome Editing in Plants: Developments and Applications
Ma, X., Zhu, Q., Chen, Y., & Liu, Y. (2016) · Molecular Plant · doi:10.1016/j.molp.2016.04.009 · Cited by 497
Organoids: Modeling Development and the Stem Cell Niche in a Dish
Kretzschmar, K., & Clevers, H. C. (2016) · Developmental Cell · doi:10.1016/j.devcel.2016.08.014 · Cited by 496
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer
Wang, S.-W., Gao, C., Zheng, Y.-M., Yi, L., Lu, J.-C., Huang, X.-Y., Cai, J.-B., Zhang, P.-F., Cui, Y.-H., & Ke, A.-W. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01518-8 · Cited by 478
Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9
Mandal, P. K., Ferreira, L. M. R., Collins, R., Meissner, T. B., Boutwell, C. L., Friesen, M., Vrbanac, V., Garrison, B. S., Stortchevoi, A., Bryder, D., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.10.004 · Cited by 475
“nuclease to a specific DNA sequence (Cong et al., 2013; Jinek et al., 2012; Jinek et al., 2013; Mali et al., 2013).”
CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations
Cullot, G., Boutin, J., Toutain, J., Prat, F., Pennamen, P., Rooryck, C., Teichmann, M., Rousseau, E., Lamrissi-Garcia, I., Guyonnet-Duperat, V., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09006-2 · Cited by 474
Veres, A., Gosis, B. S., Ding, Q., Collins, R., Ragavendran, A., Brand, H., Erdin, S., Cowan, C. A., Talkowski, M. E., & Musunuru, K. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.04.020 · Cited by 474
An enhanced CRISPR repressor for targeted mammalian gene regulation
Yeo, N. C., Chavez, A., Lance‐Byrne, A., Chan, Y., Menn, D. J., Milanova, D., Kuo, C., Guo, X., Sharma, S., Tung, A., et al. (2018) · Nature Methods · doi:10.1038/s41592-018-0048-5 · Cited by 489
Modeling Alzheimer’s disease with iPSC-derived brain cells
Penney, J., Ralvenius, W. T., & Tsai, L.-H. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0468-3 · Cited by 471
Targeted disruption of DNMT1, DNMT3A and DNMT3B in human embryonic stem cells
Liao, J., Karnik, R., Gu, H., Ziller, M. J., Clement, K., Tsankov, A. M., Akopian, V., Gifford, C. A., Donaghey, J., Galonska, C., et al. (2015) · Nature Genetics · doi:10.1038/ng.3258 · Cited by 497
Synthetic lethality as an engine for cancer drug target discovery
Huang, A., Garraway, L. A., Ashworth, A., & Weber, B. L. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0046-z · Cited by 490
Ousterout, D. G., Kabadi, A. M., Thakore, P. I., Majoros, W. H., Reddy, T. E., & Gersbach, C. A. (2015) · Nature Communications · doi:10.1038/ncomms7244 · Cited by 470
Chromatin changes in response to drought, salinity, heat, and cold stresses in plants
Kim, J.-M., Sasaki, T., Ueda, M., Sako, K., & Seki, M. (2015) · Frontiers in Plant Science · doi:10.3389/fpls.2015.00114 · Cited by 482
Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells
Hess, G. T., Frésard, L., Han, K., Lee, C. H., Li, A., Cimprich, K. A., Montgomery, S. B., & Bassik, M. C. (2016) · Nature Methods · doi:10.1038/nmeth.4038 · Cited by 474
Sun, Y., Jiao, G., Liu, Z., Zhang, X., Li, J., Guo, X., Du, W., Du, J., Francis, F., Zhao, Y., et al. (2017) · Frontiers in Plant Science · doi:10.3389/fpls.2017.00298 · Cited by 484
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies
Gomes‐Silva, D., Srinivasan, M., Sharma, S., Lee, C. M., Wagner, D. L., Davis, T., Rouce, R. H., Bao, G., Brenner, M. K., & Mamonkin, M. (2017) · Blood · doi:10.1182/blood-2017-01-761320 · Cited by 477
Efficient CRISPR/Cas9 genome editing with low off-target effects in zebrafish
Hruscha, A., Krawitz, P. M., Rechenberg, A., Heinrich, V., Hecht, J., Haass, C., & Schmid, B. (2013) · Development · doi:10.1242/dev.099085 · Cited by 486
SCF TIR1/AFB -Based Auxin Perception: Mechanism and Role in Plant Growth and Development
Salehin, M., Bagchi, R., & Estelle, M. A. (2015) · The Plant Cell · doi:10.1105/tpc.114.133744 · Cited by 471
Gupta, R., Somyajit, K., Narita, T., Maskey, E., Stanlie, A., Kremer, M., Typas, D., Lammers, M., Mailand, N., Nussenzweig, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.050 · Cited by 480
One-step generation of knockout pigs by zygote injection of CRISPR/Cas system
Hai, T., Teng, F., Guo, R., Li, W., & Zhou, Q. (2014) · Cell Research · doi:10.1038/cr.2014.11 · Cited by 466
Kim, M. Y., Yu, K., Kenderian, S. S., Ruella, M., Chen, S., Shin, T., Aljanahi, A. A., Schreeder, D. M., Klichinsky, M., Shestova, O. E., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.013 · Cited by 467
Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing
Naeem, M., Majeed, S., Hoque, M. Z., & Ahmad, I. (2020) · Cells · doi:10.3390/cells9071608 · Cited by 457
Efficient genome editing in filamentous fungus Trichoderma reesei using the CRISPR/Cas9 system
Liu, R., Chen, L., Jiang, Y., Zhou, Z., & Zou, G. (2015) · Cell Discovery · doi:10.1038/celldisc.2015.7 · Cited by 467
Metadata
- Authors
- Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., & Zhang, F.
- Affiliations
- Broad Institute (US)
- Columbia University (US)
- Koch Institute for Integrative Cancer Research At MIT (US)
- Rockefeller University (US)
- Corresponding author
- Cong, Le
- Ran, F. Ann
- Zhang, Feng
- ORCID
- Venue
- Science
- Published
- 2013-02-15
- Volume
- 339
- Issue
- 6121
- Pages
- 819-823
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3795411
- OpenAlex
- W2064815984
- Semantic Scholar
- 51bcf2a1577b3dd876fcaa4cdf630f54d261c107
- Cited by
- 15,339
- References
- 32
- Citations by year
- 2026: 614 · 2025: 926 · 2024: 1041 · 2023: 1127 · 2022: 1311 · 2021: 1421 · 2020: 1456 · 2019: 1399 · 2018: 1464 · 2017: 1368 · 2016: 1261 · 2015: 888 · 2014: 732 · 2013: 305
- FWCI
- 476.05
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- PMC
- Funders
- Howard Hughes Medical Institute
- National Institute of Mental Health (DP1MH100706)
- National Cancer Institute (R01CA133404)
- National Institute of General Medical Sciences (R01GM034277, R01 GM34277, T32GM007753)
- National Institute of Allergy and Infectious Diseases (DP2AI104556)
- National Institute of Neurological Disorders and Stroke (R01NS073124)
- National Center for Chronic Disease Prevention and Health Promotion (DP1‑MH100706)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- CRISPR/Cas9, genome editing, RNA-guided DNA cleavage, nicking enzyme, homology-directed repair, single guide RNA, CRISPR arrays, human cells, mouse cells, mutagenesis
- MeSH terms
- Animals, Base Sequence, DNA, Genetic Engineering, Humans, Molecular Sequence Data, RNA, Streptococcus pyogenes, Mutagenesis, Genome, Microarray Analysis, Mice, DNA Cleavage, Inverted Repeat Sequences, Genetic Loci, Recombinational DNA Repair, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
